BR112020003735A2 - método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais - Google Patents
método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais Download PDFInfo
- Publication number
- BR112020003735A2 BR112020003735A2 BR112020003735-4A BR112020003735A BR112020003735A2 BR 112020003735 A2 BR112020003735 A2 BR 112020003735A2 BR 112020003735 A BR112020003735 A BR 112020003735A BR 112020003735 A2 BR112020003735 A2 BR 112020003735A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral
- arginine
- mimetic
- analog
- tranexamic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550656P | 2017-08-27 | 2017-08-27 | |
| US62/550656 | 2017-08-27 | ||
| US201862664555P | 2018-04-30 | 2018-04-30 | |
| US62/664555 | 2018-04-30 | ||
| PCT/US2018/046023 WO2019045989A1 (en) | 2017-08-27 | 2018-08-09 | METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020003735A2 true BR112020003735A2 (pt) | 2020-09-01 |
Family
ID=65525881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020003735-4A BR112020003735A2 (pt) | 2017-08-27 | 2018-08-09 | método e composição para tratar, prevenir ou reduzir epidemias virais de ocorrência única ou recorrentes, suprimir o desenvolvimento ou o crescimento de infecções virais crônicas, ou para prevenir ou tratar infecções virais |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11413279B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4681713A2 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2020531586A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102706114B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111315374A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018324427B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020003735A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3073685A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2020002156A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019045989A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202001472B (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220249416A1 (en) * | 2019-10-29 | 2022-08-11 | Tranexamic Technologies, Llc | Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy |
| WO2021162879A1 (en) * | 2020-02-14 | 2021-08-19 | Tranexamic Technologies, Llc | Methods and compositions for antimicrobial use of synthetic lysine analogs, derivatives, mimetics, and prodrugs |
| JP7830159B2 (ja) * | 2021-02-26 | 2026-03-16 | ライオン株式会社 | コロナウイルスの細胞侵入抑制剤 |
| EP4659805A3 (en) | 2022-02-09 | 2026-04-01 | Galen Limited | Concentrated injectable tranexamic acid compositions and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69524971T2 (de) * | 1994-10-28 | 2002-08-29 | Vitaleech Bioscience N.V., Rotterdam | Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen |
| AU1773600A (en) * | 1998-12-21 | 2000-07-12 | Aps Kbus 8 Nr. 4788 | Topical treatment of skin disease |
| ES2156731B1 (es) * | 1999-05-31 | 2002-02-16 | Grifols Grupo Sa | Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano. |
| US7056947B2 (en) * | 2002-07-05 | 2006-06-06 | Georgia Tech Research Corp. | Aza-peptide epoxides |
| AU2003272974A1 (en) * | 2002-10-11 | 2004-05-04 | Daiichi Pharmaceutical Co., Ltd. | Anti-influenza virus agent |
| JP2008115168A (ja) * | 2006-10-12 | 2008-05-22 | Daiichi Sankyo Healthcare Co Ltd | 抗アデノウイルス剤 |
| CA2742817A1 (en) * | 2008-11-20 | 2010-05-27 | Biogen Idec Ma Inc. | Arginine inactivation of viruses |
| JP2010189301A (ja) * | 2009-02-17 | 2010-09-02 | Toshihito Eto | 新型インフルエンザ感染症に対する医薬組成物およびその利用 |
| US20120082677A1 (en) * | 2010-10-01 | 2012-04-05 | Sherif Salah Abdul Aziz | Compositions for the treatment of hcv and hbv |
| US20140271923A1 (en) * | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| CN103405384B (zh) * | 2013-09-01 | 2015-05-13 | 吴静 | 氨甲环酸的药物组合物 |
-
2018
- 2018-08-09 CN CN201880070088.0A patent/CN111315374A/zh active Pending
- 2018-08-09 EP EP25197729.4A patent/EP4681713A2/en not_active Withdrawn
- 2018-08-09 WO PCT/US2018/046023 patent/WO2019045989A1/en not_active Ceased
- 2018-08-09 EP EP18850491.4A patent/EP3672584A4/en not_active Withdrawn
- 2018-08-09 AU AU2018324427A patent/AU2018324427B2/en not_active Ceased
- 2018-08-09 BR BR112020003735-4A patent/BR112020003735A2/pt unknown
- 2018-08-09 CA CA3073685A patent/CA3073685A1/en active Pending
- 2018-08-09 KR KR1020207008860A patent/KR102706114B1/ko active Active
- 2018-08-09 US US16/610,504 patent/US11413279B2/en active Active
- 2018-08-09 MX MX2020002156A patent/MX2020002156A/es unknown
- 2018-08-09 JP JP2020532845A patent/JP2020531586A/ja not_active Withdrawn
-
2020
- 2020-02-26 MX MX2023009499A patent/MX2023009499A/es unknown
- 2020-03-09 ZA ZA2020/01472A patent/ZA202001472B/en unknown
-
2022
- 2022-05-25 US US17/824,602 patent/US20220288050A1/en not_active Abandoned
-
2023
- 2023-05-30 JP JP2023088440A patent/JP2023123440A/ja not_active Withdrawn
-
2024
- 2024-06-06 AU AU2024203839A patent/AU2024203839A1/en active Pending
-
2025
- 2025-08-01 JP JP2025129144A patent/JP2025166032A/ja active Pending
- 2025-09-11 US US19/326,649 patent/US20260007649A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019045989A1 (en) | 2019-03-07 |
| US20260007649A1 (en) | 2026-01-08 |
| US11413279B2 (en) | 2022-08-16 |
| AU2024203839A1 (en) | 2024-06-27 |
| EP4681713A2 (en) | 2026-01-21 |
| JP2023123440A (ja) | 2023-09-05 |
| CN111315374A (zh) | 2020-06-19 |
| MX2023009499A (es) | 2023-08-23 |
| AU2018324427A1 (en) | 2020-04-09 |
| CA3073685A1 (en) | 2019-03-07 |
| JP2020531586A (ja) | 2020-11-05 |
| EP3672584A1 (en) | 2020-07-01 |
| EP3672584A4 (en) | 2021-05-05 |
| US20200323837A1 (en) | 2020-10-15 |
| KR20200052310A (ko) | 2020-05-14 |
| ZA202001472B (en) | 2022-05-25 |
| KR102706114B1 (ko) | 2024-09-11 |
| US20220288050A1 (en) | 2022-09-15 |
| MX2020002156A (es) | 2020-07-20 |
| JP2025166032A (ja) | 2025-11-05 |
| AU2018324427B2 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260007649A1 (en) | Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics | |
| US9387227B2 (en) | Method for treatment of sores and lesions of the skin | |
| SA96160590B1 (ar) | تركيبة صيدلانية | |
| JP7399976B2 (ja) | Covid-19新型コロナ肺炎を予防又は治療する医薬品、食品及びその使用 | |
| JPS59130223A (ja) | 相乗作用を示す抗ヘルペス組成物 | |
| BR122023026038A2 (pt) | Usos de um ácido e de um modulador de autofagia e de lipofagia | |
| WO2021198940A1 (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
| US20120071498A1 (en) | Therapeutic composition to treat lesions caused by herpes simplex virus | |
| BR112017024399B1 (pt) | Composição farmacêutica antiviral de uso tópico | |
| DK2374461T3 (en) | Piroxicam for the prophylactic and therapeutic treatment of herpes infections | |
| PT653939E (pt) | Utilizacao de um veneno de himenoptero para o fabrico de um medicamento para o tratamento de infeccoes por virus de adn | |
| Wu et al. | IcyHot analgesic topical cream limits cardiac injury in rodents | |
| HK40026056A (en) | Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics | |
| US11819508B2 (en) | Miltefosine for the treatment of viral infections including covid-19 | |
| US20250177335A1 (en) | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for modulating autophagy and lipophagy | |
| BR102020014414B1 (pt) | Formulação contendo análogo de nucleosídeo em associação com lisina para o tratamento e profilaxia do herpes | |
| EP4734970A1 (en) | Composition comprising hinokitiol and zinc salt for use in the treatment of herpes labialis | |
| WO2024236145A1 (en) | Long term treatment of hair loss | |
| US20230414557A1 (en) | New therapy concept for the treatment of corona infections, especially covid-19 infections | |
| WO2021224659A1 (es) | Composición farmacéutica y kit-de-partes para ser usados frente a infecciones causadas por corona virus | |
| CN114929212A (zh) | 用于增强功效的合成的赖氨酸类似物、衍生物、模拟物或前药与药剂的协同组合 | |
| BR102020014414A2 (pt) | Formulação contendo análogo de nucleosídeo em associação com lisina para o tratamento e profilaxia do herpes | |
| JP2009542703A (ja) | 口唇ヘルペス(単純疱疹)の局所治療のための抗ウイルス組成物およびそれを用いる方法 | |
| Iankova | P362 Topical acyclovir in the treatment of erythema annulare centrifugum | |
| US20160199318A1 (en) | Anti-Viral Compound and Composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |